Sumaya Samadi

Dr. Sumaya Samadi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SCShamikha Cheema
Shamikha Cheema
SHSyed Ibad Hussain
Syed Ibad Hussain
MFMuhammad Shaheer Bin Faheem
Muhammad Shaheer Bin Faheem
AJAmna Amir Jalal
Amna Amir Jalal
MRMohamed Rifai
Mohamed Rifai
SSSumaya Samadi
Sumaya Samadi
Introduction: Heavy metal pollution is a concerning cardiovascular risk factor and a major public health concern. While traditional cardiovascular disease (CVD) risk factors are well-established, environmental exposures are less recognized, despite their growing significance. Methods: Adhering to PROSPERO and PRISMA guidelines, a search was conducted across PubMed, Cochrane, and Embase until April 2025 for studies involving patients with heart disease or stroke who were exposed to heavy metals. Primary outcomes were the events of CVD, CHD, and stroke. Proportions of events within populations with 95% confidence intervals were pooled. R software was used for the analysis, with statistical significance set at p < 0.05. Results: We included 16 studies involving 324,331 participants. The cadmium subgroup showed a pooled proportion of 0.09 (95% CI: 0.01–0.17), with individual values ranging from 0.01 to 0.22; the arsenic subgroup showed a pooled proportion of 0.04 (95% CI: 0.04–0.04). The overall pooled proportion was 0.08 (95% CI: 0.01–0.15). Six studies found cases of CHD in groups exposed to cadmium and arsenic, with combined rates of 0.10 (95% CI: 0.00–0.22) for cadmium and 0.00 (95% CI: 0.00–0.00) for arsenic. The overall pooled proportion was 0.08 (95% CI: 0.00–0.18). Ten studies assessed CVD proportions by metal exposure. Arsenic showed a pooled proportion of 0.06 (95% CI: 0.00–0.18), cadmium 0.14 (95% CI: 0.00–0.31), lead 0.08 (95% CI: 0.01–0.14), and mercury 0.05 (95% CI: 0.04–0.06). The overall pooled proportion was 0.10 (95% CI: 0.03–0.17). Conclusion: This study emphasizes the significance of the toxic environmental metals contributing to cardiovascular risk beyond behavioural risk factors.

4 August 2025 in Brain and Behavior
Verified
Journal Article
Open access
SHSyed Tawassul Hassan
Syed Tawassul Hassan
MFMuhammad Shaheer Bin Faheem
Muhammad Shaheer Bin Faheem
YSYasmeen Sufi
Yasmeen Sufi
ANAnushah Nadeem
Anushah Nadeem
WSWajeeha Siddiqui
Wajeeha Siddiqui
SSSumaya Samadi
Sumaya Samadi
Objectives: Diabetes mellitus (DM) has a strong bidirectional relationship with mental disorders, collectively increasing the risk of mortality. We aim to analyze the mortality trends related to DM and associated mental disorders while exploring demographic and regional disparities in the United States from 1999 to 2023.Methods: Death records were obtained from the Centers for Disease Control and Prevention‐Wide‐ranging ONline Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2023. Crude and age‐adjusted mortality rates (AAMRs), measured per 100,000 people, were calculated and standardized to the 2000 US standard population. Annual percent changes (APCs) in AAMRs and crude mortality rates (CMRs) were computed through the Joinpoint regression program and data stratification was done based on sex, race, age, and geographical regions.Results: A total of 1,332,198 death records indicated the presence of both DM and mental disorders. AAMR increased fourfold from 1999 (9.5) to 2023 (40.4) per 100,000 population. Notable increase shifts were noted in AAMR across different periods between 1999 and 2021 (APC: 1999–2005: 14.98; 2005–2018: 2.92; 2018–2021: 8.98), after which it declined sharply until 2023 (APC: −6.42). Males (36.8) had elevated AAMRs in comparison to females (22.4). Non‐Hispanic (NH) American Indians contributed to most of the AAMR (39.8). CMR was 11‐fold higher in older adults as compared to those aged between 35 and 64 years. Regionally, AAMRs in nonmetropolitan areas (35.9) and Midwest regions (34.7) were the highest.Conclusions: Further research and targeted interventions are needed for in‐depth evaluation of these rising mortality trends to find the root cause and lower the burden of DM and associated mental disorders.

10 October 2025 in Journal of Epidemiology and Global Health
Verified
Journal Article
Open access
PDF file
MAMuhammad Ahmed
Muhammad Ahmed
SSShaheer Bin Shafiq
Shaheer Bin Shafiq
JRJunaid Razzak
Junaid Razzak
KMKhubaib Tariq Mansoor
Khubaib Tariq Mansoor
MNMuhammad Abdullah Naveed
Muhammad Abdullah Naveed
SNSivaram Neppala
Sivaram Neppala
Background Stroke is a leading cause of death in the U.S., with mortality trends influenced by hyperlipidemia, a significant risk factor for atherosclerosis and cardiovascular disease that can lead to ischemic stroke. This analysis examines stroke-related mortality in hyperlipidemia among adults aged 25 and older from 1999 to 2023. Methods A retrospective analysis of CDC WONDER investigated trends in mortality from Stroke (ICD codes: I60-I69) among Hyperlipidemia patients (ICD codes: E78.0, E78.1, E78.3, E78.4, E78.5) aged 25 and older. Joinpoint regression analysis calculated age-adjusted mortality rates (AAMR) per 100,000 individuals, annual percentage changes (APC), Average Annual Percent Change (AAPC), and 95% confidence intervals. Results Between 1999 and 2023, stroke and hyperlipidemia caused 241,308 deaths, with AAMRs of 1.38 in 1999 and 7.46 in 2023, an AAPC of + 7.16 (95% CI: 6.66 to 8.52). Adult men had higher AAMRs than women, with increases for both sexes [AAPC: + 7.20 vs. + 7.10; p < 0.001]. Black individuals had the highest AAMRs, followed by Hispanics. AAMR rose for all races, notably for Blacks/African Americans (AAPC: + 8.63%) and adults aged 65 and above (AAPC: + 7.35%). Northeast regions have the highest AAMRs, with the Midwest showing the most significant rise (AAPC: + 7.86%). AAMRs varied by state, from 2.0 in Georgia to 9.43 in Vermont in 2023. Non-metropolitan areas had higher AAMRs (4.31) than metropolitan areas (3.54). Conclusion This analysis reveals significant demographic and racial disparities in Stroke mortality among U.S. adults with Hyperlipidemia, which highlights the urgent need for targeted, equity-focused interventions to address these disparities.

27 August 2025 in Health Science Reports
Verified
Journal Article
Open access
MFMuhammad Shaheer Bin Faheem
Muhammad Shaheer Bin Faheem
MHMuhammad Haroon‐Ul‐Rasheed
Muhammad Haroon‐Ul‐Rasheed
RARohma Aftab
Rohma Aftab
QFQasra Faheem
Qasra Faheem
FFFaheem Feroze
Faheem Feroze
SSSumaya Samadi
Sumaya Samadi
Background and Aims: Parkinson's disease (PD) is a progressive neurological condition that consists of both motor and non‐motor symptoms that considerably deteriorate the quality of life. Pharmacological treatments, primarily levodopa, have been used to manage PD. However, side effects such as dyskinesias and motor fluctuations frequently limit their long‐term effectiveness. In recent decades, breakthroughs and innovations in neurosurgical treatments have transformed the entire treatment landscape. Methods: This narrative review looks at clinical research focused on neurosurgical, gene therapy, and other modern methods for treating PD. Forty‐seven studies were included in the search from PubMed, while three others were taken from other databases. Results: Deep brain stimulation (DBS) is the most established neurosurgical technique, and has strong evidence that it can improve motor symptoms. Focused ultrasound (FUS) provides a noninvasive option, but the majority of studies related to it still lack long‐term data. Gene therapy strategies like AAV2‐hAADC and ProSavin have shown early‐phase safety and efficacy, but are still in early clinical stages. Newer imaging techniques and robotic surgery can play a critical role PD‐related surgery, in the future. Conclusion: The range of PD treatment options is growing because of the newer neurosurgical and gene therapy approaches. The current results are promising, but larger‐scale, controlled trials are required to show long‐term safety and efficacy.

2 December 2025 in Journal of Arrhythmia
Verified
Journal Article
Open access
MFMuhammad Shaheer Bin Faheem
Muhammad Shaheer Bin Faheem
TATehreem Asghar
Tehreem Asghar
FFFaheem Feroze
Faheem Feroze
FNFatima Naveed
Fatima Naveed
NCNatasha Chowdhury
Natasha Chowdhury
MFMarat Fudim
Marat Fudim
Background: Sudden cardiac arrest is a leading cause of cardiovascular mortality, often occurring without warning and resulting in high fatality rates. Despite advances in prevention and emergency response, disparities in mortality remain rampant across demographic and geographic groups. This study examines long‐term trends in sudden cardiac arrest‐related mortality in the United States from 1999 to 2023, stratified by sex, race/ethnicity, region, and urbanization level. Methods: Mortality data was extracted from the CDC WONDER database. Age‐adjusted mortality rates (AAMRs) were calculated per 100 000 persons using the 2000 U.S. standard population. Joinpoint regression analysis was applied to estimate annual percent changes (APCs) and identify significant shifts in mortality trends. Results: A total of 8 523 980 SCA deaths were reported during the study period. Overall, the AAMR declined from 196.03 in 1999 to 131.55 in 2023, with the most marked reductions observed after 2021 (APC: –9.63; 95% CI: −13.51 to −5.20; p < 0.000001). Men consistently exhibited higher AAMRs than women (156.08 vs. 111.09 in 2023). Non‐Hispanic Black individuals had the highest mortality rates (235.18), followed by Hispanics (184.38). Geographic disparities were evident, with the Northeast and metropolitan areas reporting the greatest AAMRs. Conclusions: Mortality due to sudden cardiac arrest has declined substantially over the past 25 years, likely driven by improvements in cardiovascular prevention, acute care, and resuscitation practices. However, significant sex, racial, and regional disparities persist, highlighting the need for interventions that are tailored to reduce inequities and improve survival from sudden cardiac arrest.

16 July 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MFMuhammad Shaheer Bin Faheem
Muhammad Shaheer Bin Faheem
NZNafila Mbbs Zeeshan
Nafila Mbbs Zeeshan
SRSyed Atta Ur Rafe
Syed Atta Ur Rafe
SSSumaya Samadi
Sumaya Samadi
Introduction: Bickerstaff brainstem encephalitis (BBE) is a rare autoimmune neurological disorder first identified in 1951. It shares clinical and immunological features with Guillain–Barré syndrome (GBS) and Miller–Fisher syndrome (MFS). BBE, characterized by brainstem dysfunction, often after infection or vaccination, is characterized by immunopathogenesis involving microbial antigens and neural gangliosides, with anti-GQ1b IgG antibodies as key biomarkers. Methods: A comprehensive narrative review was conducted by searching PubMed, Cochrane, Global Health Library, and Google Scholar for relevant literature up to 2025. Keywords included, “BBE syndrome,” “Miller Fisher syndrome,” “GBS syndrome,” “anti-GQ1b antibody syndrome,” and “autoimmune encephalitis.” The Scale for the Assessment of Narrative Review Articles (SANRA) was utilized to ensure manuscript quality. Results: Most cases of BBE have positive anti-GQ1b IgG antibodies, and the condition usually manifests as ophthalmoplegia, ataxia, and reduced consciousness. Cerebrospinal fluid examination frequently shows higher protein levels, and MRI results may reveal midbrain lesions. BBE, GBS, and MFS all have a pathogenic spectrum, which points to a continuum of post-infectious autoimmunity. Intravenous immunoglobulin (IVIG) and plasmapheresis are the main treatment approaches; both have been shown to be effective in reducing symptoms and hastening recovery. The use of corticosteroids as an adjuvant treatment is possible. Pediatric patients tend to heal more quickly, and the prognosis is generally good, however severe instances may necessitate intensive care. Conclusion: BBE is a rare disorder requiring early recognition and immunotherapy. Detection of anti-GQ1b IgG antibodies differentiates it from other neurological conditions. Further research is needed for standardization and improved outcomes.